Skip to main content
Karolinska Development logo

Karolinska Development — Investor Relations & Filings

Ticker · KDEV ISIN · SE0002190926 LEI · 54930011ZA52NKO5W681 ST Financial and insurance activities
Open in API
Filings indexed 761 across all filing types
Latest filing 2026-01-09 Capital/Financing Update
Country SE Sweden
Listing ST KDEV

About Karolinska Development

https://www.karolinskadevelopment.com/en

Karolinska Development is an investment company specializing in the life sciences sector. It identifies, finances, and supports the creation and growth of companies developing innovative medical technologies and pharmaceuticals. The firm manages a diversified portfolio of biotechnology and medtech ventures, often originating from academic research, with the goal of developing ground-breaking treatments for severe diseases. Karolinska Development leverages its team's expertise in research, development, and commercialization to guide its portfolio companies, providing both capital and strategic support to advance innovations toward the market.

Recent filings

Filing Released Lang Actions
Karolinska Development AB (publ) offentliggör informationsdokument med anledning av förestående företrädesemission
Capital/Financing Update Classification · 1% confidence The document is a press release from Karolinska Development AB announcing the publication of an 'information document' (informationsdokument) related to a rights issue (företrädesemission). It provides details on the timeline, advisors, and legal disclaimers regarding the offering. It explicitly states that the information document itself is available on the company's website and has been registered with the Swedish Financial Supervisory Authority. Following the 'Menu vs Meal' rule, this is an announcement of a report/document rather than the report itself, making it a Report Publication Announcement (RPA).
2026-01-09 Swedish
Karolinska Development AB (publ) announces publication of information document in connection with upcoming rights issue
Report Publication Announcement Classification · 1% confidence The document is a press release announcing the publication of an 'information document' related to a rights issue. It explicitly states that the company is announcing the publication of this document and provides a link to where it can be found. Following the 'Menu vs Meal' rule, since this is an announcement about the availability of a report rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2026-01-09 English
Karolinska Development’s Extraordinary General Meeting 2026
AGM Information Classification · 1% confidence The document details the outcomes of an Extraordinary General Meeting (EGM), specifically focusing on the approval of a rights issue (share issuance) and amendments to the Articles of Association. While it mentions voting results, the primary substance is the announcement of a capital increase (rights issue) and corporate structural changes. Given the specific focus on the capital raise and the EGM context, 'SHA' (Share Issue/Capital Change) is the most accurate classification for the corporate action described.
2026-01-08 English
Karolinska Developments extra bolagsstämma 2026
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document reports the results of an 'extra bolagsstämma' (extraordinary general meeting) held by Karolinska Development AB. It details the specific resolutions passed by shareholders, including the approval of a new share issue (rights issue) and amendments to the articles of association (company name change and capital limits). Since the document provides the official results of shareholder votes at a general meeting, it falls under the category of Declaration of Voting Results & Voting Rights Announcements.
2026-01-08 Swedish
Karolinska Development’s portfolio company AnaCardio presents positive top-line data from the phase 2a study of its drug candidate AC01
Regulatory Filings Classification · 1% confidence The document is a press release announcing positive clinical trial results for a portfolio company (AnaCardio) of Karolinska Development AB. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general corporate announcement regarding business operations and clinical progress, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate news.
2025-12-10 English
Karolinska Developments portföljbolag AnaCardio presenterar positiva top line-resultat från fas 2a-studien med läkemedelskandidaten AC01
Regulatory Filings Classification · 1% confidence The document is a press release issued by Karolinska Development AB announcing positive clinical trial results for its portfolio company, AnaCardio. It details the outcome of a Phase 2a study (GOAL-HF1) for the drug candidate AC01. Since this is a corporate announcement regarding business/operational developments (clinical trial results) and does not fit into specific categories like financial reports, dividends, or governance, it falls under the general regulatory announcement category.
2025-12-10 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.